<DOC>
	<DOCNO>NCT00930514</DOCNO>
	<brief_summary>This 2 stage study compare pharmacokinetics safety profile subcutaneous intravenous rituximab participant follicular lymphoma . In first stage , participant achieve least partial response induction treatment intravenous rituximab randomize one 3 treatment cohort , receive rituximab 375 milligram per square meter ( mg/m^2 ) intravenously , 375 mg/m^2 subcutaneously 625 mg/m^2 subcutaneously , pharmacokinetics evaluate ongoing basis . Upon selection subcutaneous dose ( 800 mg/m^2 ) result rituximab trough plasma concentration ( C trough ) value comparable achieve intravenous formulation , participant second stage study randomize receive either subcutaneous intravenous formulation demonstrate comparability C trough level rout administration . Maintenance therapy continue every 2 3 month subcutaneous formulation .</brief_summary>
	<brief_title>A Pharmacokinetic Study Subcutaneous Intravenous Rituximab Participants With Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>CD20positive follicular nonHodgkin 's lymphoma ( NHL ) Documented partial complete response end induction treatment rituximab Must complete induction treatment , receive least 1 dose intravenous rituximab maintenance treatment Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; = ) 2 Life expectancy great equal ( &gt; = ) 6 month Histological evidence transformation NHL , type NHL follicular lymphoma Presence history central nervous system disease History malignancy follicular NHL Recent major surgery ( within 4 week prior screen ) , exclude lymph node biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>